Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
Open Access
- 7 February 2020
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
Abstract
No abstract availableThis publication has 74 references indexed in Scilit:
- Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory PatientsThe Oncologist, 2015
- Treatment strategies for radioactive iodine-refractory differentiated thyroid cancerTherapeutic Advances in Medical Oncology, 2014
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet, 2014
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsCancer Letters, 2013
- Progress in molecular-based management of differentiated thyroid cancerThe Lancet, 2013
- Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directionsExpert Review of Endocrinology & Metabolism, 2012
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 KinaseClinical Cancer Research, 2008
- E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibitionInternational Journal of Cancer, 2007
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyJournal of Clinical Endocrinology & Metabolism, 2006